INTERCOSTAL NERVE BLOCK: Efficacy of CINB for Patients With Multiple Rib Fractures

Last updated: March 26, 2025
Sponsor: Zachary Warriner
Overall Status: Active - Recruiting

Phase

4

Condition

Chest Trauma

Treatment

Ropivacaine

Non steroidal anti-inflammatory drug and opioids

Clinical Study ID

NCT05642026
SURMI-22-INTERCOSTAL-NB
  • Ages > 18
  • All Genders

Study Summary

This is a prospective, randomized, non-blinded study comparing CINB plus medical therapy versus standard medical care (non-steroidals and opioids intravenous/oral inpatient and oral outpatient) alone for patients with multiple rib fractures. The objective of this study is to analyze the effect of continuous intercostal nerve block (CINB) in the treatment of patients admitted to the adult trauma service with rib fractures. The effectiveness of CINB as adjunctive treatment will be compared to standard medical therapy involving nonsteroidal and intravenous/oral opioid medications.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subjects will be at least 18 years old

  • Subjects will have 2 or more identified rib fractures

  • Subjects will be willing to provide informed consent for procedure

  • Subjects will be identified as appropriate for initiation of continuous nerve blocktherapy for treatment of rib fracture associated pain.

Exclusion

Exclusion Criteria:

  • Documented allergy to study medication

  • Epidural catheter use

  • Prisoners

  • Refusal of CINB therapy

Study Design

Total Participants: 180
Treatment Group(s): 2
Primary Treatment: Ropivacaine
Phase: 4
Study Start date:
September 01, 2025
Estimated Completion Date:
February 01, 2026

Connect with a study center

  • University of Kentucky Medical Center

    Lexington, Kentucky 40536
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.